{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:46:34Z","timestamp":1792784794811,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"vor","delay-in-days":211,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"European Union Horizon 2020","award":["825828"],"award-info":[{"award-number":["825828"]}],"id":[{"id":"https:\/\/ror.org\/019w4f821","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Applied Materials and Nano- technology Center of Excellence, Miskolc University","id":[{"id":"https:\/\/ror.org\/02y9qjz38","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.addr.2020.07.024","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T21:34:49Z","timestamp":1596231289000},"page":"163-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":689,"special_numbering":"C","title":["Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals"],"prefix":"10.1016","volume":"154-155","author":[{"given":"Gergely Tibor","family":"Kozma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janos","family":"Szebeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2020.07.024_bb0005","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.4155\/fmc.14.125","article-title":"PEGylation and its impact on the design of new protein-based medicines","volume":"6","author":"Ginn","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.addr.2020.07.024_bb0010","doi-asserted-by":"crossref","DOI":"10.1590\/s2175-97902018000001009","article-title":"Protein PEGylation for the design of biobetters: from reaction to purification processes","volume":"54","author":"Santos","year":"2018","journal-title":"Braz. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2020.07.024_bb0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/JEP.S148944","article-title":"Polyethylene glycol in spinal cord injury repair: a critical review","volume":"10","author":"Lu","year":"2018","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.addr.2020.07.024_bb0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0169-409X(95)00026-4","article-title":"The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres","volume":"16","author":"Gref","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2020.07.024_bb0025","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2174\/138161280406221011110509","article-title":"Cellular camouflage: fooling the immune system with polymers","volume":"4","author":"Scott","year":"1998","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.addr.2020.07.024_bb0030","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0169-409X(02)00026-1","article-title":"PEGylated antibodies and antibody fragments for improved therapy: a review","volume":"54","author":"Chapman","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2020.07.024_bb0035","series-title":"PEGylated Protein Drugs: Basic Science and Clinical Applications","first-page":"147","article-title":"The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol)","author":"Armstrong","year":"2009"},{"key":"10.1016\/j.addr.2020.07.024_bb0040","first-page":"4185","article-title":"Application of poly(ethylene glycol)-distearoylphosphatidylethanolamine (PEG-DSPE) block copolymers and their derivatives as nanomaterials in drug delivery","volume":"7","author":"Wang","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2020.07.024_bb0045","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","article-title":"PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs","volume":"105","author":"Turecek","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2020.07.024_bb0050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2020.07.024_bb0055","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s13346-019-00631-4","article-title":"PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution","volume":"9","author":"Hussain","year":"2019","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.addr.2020.07.024_bb0060","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12079-018-0492-0","article-title":"Protein PEGylation for cancer therapy: bench to bedside","volume":"13","author":"Gupta","year":"2019","journal-title":"J. Cell Commun. Signal."},{"key":"10.1016\/j.addr.2020.07.024_bb0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12929-019-0589-7","article-title":"Structural basis of polyethylene glycol recognition by antibody","volume":"27","author":"Lee","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.addr.2020.07.024_bb0070","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jim.2019.03.004","article-title":"Depletion of interfering IgG and IgM is critical to determine the role of IgE in pegvaliase-associated hypersensitivity","volume":"468","author":"Larimore","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.addr.2020.07.024_bb0075","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/eurheartj\/ehs232","article-title":"A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial","volume":"34","author":"Povsic","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2020.07.024_bb0080","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/pds.3655","article-title":"Relative safety of peginesatide and epoetin alfa","volume":"23","author":"Weinhandl","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.addr.2020.07.024_bb0085","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13075-017-1396-8","article-title":"Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout","volume":"19","author":"Calabrese","year":"2017","journal-title":"Arth. Res. Ther."},{"key":"10.1016\/j.addr.2020.07.024_bb0090","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2215\/CJN.03570417","article-title":"Efficacy and long-term safety of C.E.R.A. maintenance in pediatric hemodialysis patients with anemia of CKD","volume":"13","author":"Fischbach","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.07.024_bb0095","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ajo.2006.10.007","article-title":"Vitreous injections of pegaptanib sodium triggering allergic reactions","volume":"143","author":"Steffensmeier","year":"2007","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.addr.2020.07.024_bb0100","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/1078155214542493","article-title":"Delayed hypersensitivity reaction related to the use of pegfilgrastim","volume":"21","author":"Dadla","year":"2015","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.addr.2020.07.024_bb0105","author":"Doxil"},{"key":"10.1016\/j.addr.2020.07.024_bb0110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1043454217741868","article-title":"Clinical characteristics of intravenous PEG-asparaginase hypersensitivity reactions in patients undergoing treatment for acute lymphoblastic leukemia [formula: see text]","volume":"35","author":"Browne","year":"2018","journal-title":"J. Pediatr. Oncol. Nurs."},{"key":"10.1016\/j.addr.2020.07.024_bb0115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2020.07.024_bb0120","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arth. Res. Ther."},{"key":"10.1016\/j.addr.2020.07.024_bb0125","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","article-title":"PEGylated liposomes: immunological responses","volume":"20","author":"Mohamed","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.addr.2020.07.024_bb0130","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.0c03648","article-title":"Complement activation: a potential threat of self-damaging attack on PEGylated nanomedicines","author":"Gabizon","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2020.07.024_bb0135","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1021\/bc200551b","article-title":"Role of the methoxy group in immune responses to mPEG-protein conjugates","volume":"23","author":"Sherman","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2020.07.024_bb0140","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.molimm.2013.07.014","article-title":"Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins","volume":"57","author":"Saifer","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.addr.2020.07.024_bb0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jconrel.2018.08.022","article-title":"Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo","volume":"287","author":"Grenier","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.07.024_bb0150","doi-asserted-by":"crossref","first-page":"12371","DOI":"10.1021\/acs.analchem.6b03614","article-title":"Optimization of an anti-poly(ethylene glycol) (anti-PEG) cell-based capture system to quantify PEG and PEGylated molecules","volume":"88","author":"Lin","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.addr.2020.07.024_bb0155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000233309","article-title":"Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins","volume":"70","author":"Richter","year":"1983","journal-title":"Int. Arch. Allerg. Appl. Immunol."},{"key":"10.1016\/j.addr.2020.07.024_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000233512","article-title":"Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors","volume":"74","author":"Richter","year":"1984","journal-title":"Int. Arch. Allerg. Appl. Immunol."},{"key":"10.1016\/j.addr.2020.07.024_bb0165","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2012.11.016","article-title":"Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon","volume":"165","author":"Shiraishi","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.07.024_bb0170","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/acs.molpharmaceut.5b00144","article-title":"Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein","volume":"12","author":"Mima","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2020.07.024_bb0175","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2020.07.024_bb0180","first-page":"71","article-title":"Pegloticase: withdrawal of its European marketing authorisation is welcome","volume":"26","author":"Prescrire","year":"2017","journal-title":"Prescrire Int."},{"key":"10.1016\/j.addr.2020.07.024_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2016.05.029","article-title":"The early days of PEG and PEGylation (1970s-1990s)","volume":"40","author":"Hoffman","year":"2016","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2020.07.024_bb0190","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1002\/jps.23254","article-title":"Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species","volume":"101","author":"Li","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2020.07.024_bb0195","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1248\/bpb.b12-00276","article-title":"Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response","volume":"35","author":"Shimizu","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2020.07.024_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2005.01.008","article-title":"Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats","volume":"104","author":"Wang","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.07.024_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0925-5710(98)00039-5","article-title":"PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques","volume":"68","author":"Francis","year":"1998","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.addr.2020.07.024_bb0210","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejps.2016.06.007","article-title":"Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice","volume":"91","author":"Poppenborg","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2020.07.024_bb0215","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/bjh.16254","article-title":"Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker","volume":"189","author":"Kloos","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.addr.2020.07.024_bb0220","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41467-017-00622-4","article-title":"A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol","volume":"8","author":"Chang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2020.07.024_bb0225","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1021\/bc100067t","article-title":"Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies","volume":"21","author":"Su","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2020.07.024_bb0230","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0022-3565(24)35391-1","article-title":"Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes","volume":"292","author":"Dams","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2020.07.024_bb0235","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0168-3659(02)00462-5","article-title":"Accelerated clearance of PEGylated liposomes in rats after repeated injections","author":"Ishida","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.07.024_bb0240","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3109\/10717544.2014.885998","article-title":"Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection","volume":"22","author":"Xu","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2020.07.024_bb0245","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijpharm.2014.09.047","article-title":"Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin","volume":"476","author":"Suzuki","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2020.07.024_bb0250","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ijpharm.2012.07.049","article-title":"Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs","volume":"436","author":"Suzuki","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2020.07.024_bb0255","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jconrel.2003.12.011","article-title":"Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice","volume":"95","author":"Ishida","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.07.024_bb0260","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2007.02.010","article-title":"Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes","volume":"119","author":"Wang","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.07.024_bb0265","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2007.11.005","article-title":"Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes","volume":"354","author":"Ishida","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2020.07.024_bb0270","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1248\/bpb.b14-00653","article-title":"Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice","volume":"38","author":"Hashimoto","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2020.07.024_bb0275","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Abu Lila","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.07.024_bb0280","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/wnan.1339","article-title":"Anti-PEG immunity: emergence, characteristics, and unaddressed questions","volume":"7","author":"Yang","year":"2015","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2020.07.024_bb0285","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.imbio.2012.08.274","article-title":"Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon","volume":"218","author":"Shimizu","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.addr.2020.07.024_bb0290","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jconrel.2006.08.017","article-title":"Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection","volume":"115","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.07.024_bb0295","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jconrel.2006.08.001","article-title":"Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes","volume":"115","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.07.024_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics3010001","article-title":"Anti-PEG IgM response against PEGylated liposomes in mice and rats","volume":"3","author":"Ichihara","year":"2010","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2020.07.024_bb0305","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijpharm.2010.03.022","article-title":"T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes","volume":"392","author":"Koide","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2020.07.024_bb0310","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-1-62703-140-0_4","article-title":"Anti-PEG IgM production via a PEGylated nano-carrier system for nucleic acid delivery","volume":"948","author":"Ichihara","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2020.07.024_bb0315","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.imbio.2015.06.005","article-title":"Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells","volume":"220","author":"Shimizu","year":"2015","journal-title":"Immunobiology"},{"key":"10.1016\/j.addr.2020.07.024_bb0320","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2006.01.005","article-title":"Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes","volume":"112","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.07.024_bb0325","series-title":"Immune Effects of Biopharmaceuticals and Nanomedicines","first-page":"771","article-title":"Accelerated blood clearance phenomenon and complement activation-related pseudoallergy: Two sides of the same coin","author":"Abu Lila","year":"2018"},{"key":"10.1016\/j.addr.2020.07.024_bb0330","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejps.2011.11.014","article-title":"Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats","volume":"45","author":"Ma","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2020.07.024_bb0335","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil(R)--the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.07.024_bb0340","series-title":"Handbook of Clinical Nanomedicine: From Bench to Bedside, Chapter: Book Chapter 9: Publisher: Editors","first-page":"1","article-title":"Design and development of approved nanopharmaceutical products","author":"Barenholz","year":"2015"},{"key":"10.1016\/j.addr.2020.07.024_bb0345","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2020.07.024_bb0350","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.gtc.2006.09.006","article-title":"Infusion reactions and their management","volume":"35","author":"Mayer","year":"2006","journal-title":"Gastroenterol. Clin. North Am."},{"key":"10.1016\/j.addr.2020.07.024_bb0355","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.addr.2020.07.024_bb0360","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1188\/10.CJON.E10-E21","article-title":"Infusion reactions: diagnosing, asessment and management","volume":"14","author":"Vogel","year":"2010","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.addr.2020.07.024_bb0365","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1161\/01.CIR.99.17.2302","article-title":"Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody","volume":"99","author":"Szebeni","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.024_bb0370","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.addr.2020.07.024_bb0375","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.addr.2020.07.024_bb0380","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.drudis.2018.01.025","article-title":"Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement?","volume":"23","author":"Szebeni","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2020.07.024_bb0385","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.molimm.2008.08.276","article-title":"Poly (ethylene glycol) s trigger complement activation in human serum through alternative and lectin pathways: a plausible cause for anaphylaxis","volume":"46","author":"Hamad","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.addr.2020.07.024_bb0390","doi-asserted-by":"crossref","first-page":"9315","DOI":"10.1021\/acsnano.9b03942","article-title":"Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions","volume":"13","author":"Kozma","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2020.07.024_bb0395","article-title":"Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin via formation of the membrane attack complex","author":"Chen","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2020.07.024_bb0400","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pbc.25319","article-title":"PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol","volume":"62","author":"Henriksen","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.addr.2020.07.024_bb0405","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2020.07.024_bb0410","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","article-title":"Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer","volume":"137","author":"Ganson","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2020.07.024_bb0415","article-title":"Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes","volume":"2048872617703065","author":"Staudacher","year":"2017","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"10.1016\/j.addr.2020.07.024_bb0420","series-title":"Nanotechnology for Human Health","first-page":"97","article-title":"Challenges and risks of nanotechnology in medicine: An immunologist\u2019s point of view","author":"Szebeni","year":"2016"},{"key":"10.1016\/j.addr.2020.07.024_bb0425","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2020.07.024_bb0430","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1128\/IAI.67.9.4862-4869.1999","article-title":"B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity","volume":"67","author":"McCool","year":"1999","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2020.07.024_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.09.002","article-title":"Molecular insights for the biological interactions between polyethylene glycol and cells","volume":"147","author":"Xu","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2020.07.024_bb0440","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2007.05.015","article-title":"PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner","volume":"122","author":"Ishida","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.07.024_bb0445","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1248\/bpb.b13-00562","article-title":"Ex-vivo\/in-vitro anti-polyethylene glycol (PEG) immunoglobulin M production from murine splenic B cells stimulated by PEGylated liposome","volume":"36","author":"Abu Lila","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2020.07.024_bb0450","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11095-018-2505-3","article-title":"A cell assay for detecting anti-PEG immune response against PEG-modified therapeutics","volume":"35","author":"Shimizu","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2020.07.024_bb0455","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2020.07.024_bb0460","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","article-title":"Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals","volume":"88","author":"Chen","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.addr.2020.07.024_bb0465","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23071700","article-title":"Understanding the role of anti-PEG antibodies in the complement activation by doxil in vitro","volume":"23","author":"Neun","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2020.07.024_bb0470","series-title":"Engineering of Biomaterials for Drug Delivery Systems: Beyond Polyethylene Glycol","first-page":"51","article-title":"PEGylation and anti-PEG antibodies","author":"Abu Lila","year":"2018"},{"key":"10.1016\/j.addr.2020.07.024_bb0475","doi-asserted-by":"crossref","DOI":"10.3390\/polym12020298","article-title":"The importance of poly(ethylene glycol): alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation","volume":"12","author":"Hoang Thi","year":"2020","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.addr.2020.07.024_bb0480","first-page":"37","article-title":"Repeated injections of PEG-PE liposomes generate anti-PEG antibodies","volume":"10","author":"Sroda","year":"2005","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.addr.2020.07.024_bb0485","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1208\/s12248-015-9799-4","article-title":"Development of a generic anti-PEG antibody assay using bioscale\u2019s acoustic membrane microparticle technology","volume":"17","author":"Dong","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2020.07.024_bb0490","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.addr.2020.07.024_bb0495","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0731-7085(99)00244-7","article-title":"Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective","volume":"21","author":"Findlay","year":"2000","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.addr.2020.07.024_bb0500","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jpba.2005.04.045","article-title":"Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies","volume":"39","author":"Geng","year":"2005","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.addr.2020.07.024_bb0505","doi-asserted-by":"crossref","first-page":"8217","DOI":"10.1021\/acs.analchem.7b02447","article-title":"Sensitive and quantitative detection of anti-poly(ethylene glycol) (PEG) antibodies by methoxy-PEG-coated surface plasmon resonance sensors","volume":"89","author":"Zhang","year":"2017","journal-title":"Anal. Chem."},{"key":"10.1016\/j.addr.2020.07.024_bb0510","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.vascn.2011.07.003","article-title":"A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers","volume":"64","author":"Liu","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.addr.2020.07.024_bb0515","first-page":"732","article-title":"Effectiveness of detergents in blocking nonspecific binding of IgG in the enzyme-linked immunosorbent assay (ELISA) depends upon the type of polystyrene used","volume":"23","author":"Kenny","year":"1987","journal-title":"Isr. J. Med. Sci."},{"issue":"4","key":"10.1016\/j.addr.2020.07.024_bb0520","first-page":"82","article-title":"Human clinical relevance of the porcine model of pseudoallergic infusion reactions","volume":"8","author":"Szebeni","year":"2020","journal-title":"Biomedicine"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X20301083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X20301083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:52:47Z","timestamp":1759207967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X20301083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":104,"alternative-id":["S0169409X20301083"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2020.07.024","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2020.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}